FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2025 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

ProDx Health Introduces 'Assured MoFi ID' Testing Program

ProDx Health has introduced its new Assured MoFi ID Program for testing.

Eye of Love Expands 'Bloom' Collection

Eye of Love has introduced two new perfume oils from its Bloom collection.

Nobü Adds to 'Essentials' Collection

Nobü is expanding its Essentials collection with three new pleasure products.

Like a Kitten to Release 'Adventure Collection'

Pleasure brand Like a Kitten has announced that it will debut its new Adventure Collection on July 15.

Full Circle Debuts New Bullet Vibes

Pleasure brand Full Circle has introduced a new range of bullet vibrators.

Magic Silk Debuts 'Butterfly Fantasies' Collection

Magic Silk has introduced its new Butterfly Fantasies line of intimate wear.

Orion Debuts 'Vipepad' Ride-On Vibrator

Orion Wholesale has introduced the latest edition of its Vibepad ride-on vibrator.

Xgen's Dr. Mindy DeSeta Spotlighted on CBS News

CBS News has spotlighted Xgen Products resident sex therapist Dr. Mindy DeSeta on its Miami and West Palm Beach affiliate stations.

Electric Novelties Expands 'Gläs' Collection

Electric Novelties has introduced a variety of new items from its Gläs collection.

FSC Toasts Jeffrey Douglas for 30 Years of Service

n the very same evening when the adult industry was hit hard by the Supreme Court ruling supporting Texas’ controversial age verification law, HB 1181, members of the Free Speech Coalition board, staff and supporters gathered to celebrate Jeffrey Douglas’ 30 years as board chair — a fitting reflection of his reputation as an eternal optimist.

Show More